Conceptual Development of Industrial Biotechnology for Commercial Production of Vaccines and Biopharmaceuticals

Conceptual Development of Industrial Biotechnology for Commercial Production of Biopharmaceuticals and Vaccines provides insights on how to bring sustainability into biologic drug production. The cumulative facts and figures within in the book are helpful to promoters in monitoring value chain transfer process of super quality biologics for better return in profits. In addition, this is a useful reference for students, researchers and scientists in biotechnology, pharmaceutical science, medical sciences, and the R&D division of biotechnology-based industries. Conceptual development of biotechnology has taken new avenues with the integration of medical sciences, physical science, and engineering, hence this is a timely source.
The current global market for vaccines, especially COVID-19, is tremendous. Bivalent oral polio vaccine, diphtheria, tetanus-containing, and measles-containing vaccines have a high demand internationally and recombinant DNA technology and protein engineering are helpful in the production of quality bio-products.

- Informs how biotechnology and pharmaceutical industries act as central pillars for the stable production of value-added biological drugs and vaccines from genetically engineered suitable vectors like microbe or cell lines from animals, mammals or plants
- Highlights various traditional and modern techniques used for improvising the quality of suitable vectors to produce biologic drugs and vaccines under GMP manufacturing facilities
- Provides updated information on the latest microchip-based bioreactors, disposable bag bioreactors, and animal systems as bioreactors to produce biologic drugs like Smart Biomolecules (next generation therapeutics), Bio-similar drugs, Bio-betters, and antibody-drug conjugates
- Explains how the closed bioreactors with proper mechanical amendments are used for vaccine production